​Kembara Xtra - Medicine - Rh Incompatibility

​Kembara Xtra - Medicine - Rh Incompatibility 
The destruction of red blood cells (RBCs) that bear Rh surface antigens through the action of antibodies in people who are missing the antigens but have developed an immunity to them through the process of isoimmunization (sensitization).
 The following system(s) are impacted: the hematologic, lymphatic, and immunologic systems
Rh isoimmunization; Rh alloimmunization; Rh sensitization are all synonyms for one another.

Epidemiology
Incidence It most commonly affects the fetuses and neonates of isoimmunized, reproductive females; it varies according to race and ethnicity Roughly fifteen percent of the white population and lesser fractions of other races are Rh-negative, which means they may be susceptible to sensitization.

Causes and effects: etiology and pathophysiology 
Antibodies that circulate in the bloodstream that are specific for Rh antigens (antibodies that have been passed across the placenta in the event of a fetus or newborn) bind to Rh antigens on red blood cells.
Hemolysis, anemia, and an increase in bilirubin production can all be caused by the immune system's destruction of red blood cells (RBCs).
It is possible for a transplacental fetomaternal hemorrhage to occur during pregnancy; however, it most frequently takes place during birth.
The majority of cases of alloimmunization are caused by a minimal amount of fetomaternal bleeding (0.1 milliliters or less) occurring during a straightforward vaginal delivery.
Other possible triggers include the transfusion of Rh-positive blood to a recipient who is Rh-negative and the use of needles that have been contaminated with Rh-positive blood.
a complicated autosomal inheritance pattern for polypeptide Rh antigens, in which three genetic loci containing genes that are closely connected to one another carry a variety of alleles (Dd, Cc, and Ee, respectively).
People are said to have the Rh-positive status if they express the D antigen, which is also known as Rho or Rho[D]. Rh-negative individuals are those who do not possess the D antigen.
 Variant D alleles, also known as weak D and incomplete D alleles, are heterogeneous forms of the D antigen that have been changed. While some D polymorphisms may increase the likelihood of developing anti-D antibodies, others do not carry this risk. Even while this does not encompass all genetic subtypes that put a person at risk for isoimmunization, certain D variations that are likely to generate alloimmunization are typed as D-negative using the protocols that are currently in use for blood typing.
An further variant D antigen known as DEL has been discovered in a subset of people, most of whom are of Asian descent. Those who only have a partial expression of DEL are more likely to develop alloimmunization and should be treated as clinically Rh-negative. Women who have complete DEL should be considered clinically Rh-positive and do not require RhD prophylaxis since they do not run the risk of becoming sensitized to Rh-D antigens when they are exposed to them through pregnancy or blood transfusions.
Antibodies to C, c, D, E, or e can be generated in persons who are missing the specific antigen; however, only D is highly immunogenic.
Isoimmunization against Rh antigens can be acquired by susceptible individuals; it is not an inherited trait.

Risk Factors 

A sensitization reaction is possible if a Rh-positive fetus is carried by a Rh-negative pregnant woman.
 Weak D and partial D women make constitute a diverse population in and of itself.
Alloimmunization has been documented (albeit it is rare) and can result in hemolytic illness of the fetus and newborn (HDFN). Despite the fact that the patient was previously reported to be Rh-positive and treated as such, alloimmunization has been reported.
It had been thought that the native chance of isoimmunization after a Rh-positive pregnancy was around 15%, but this risk appears to be going down.
antepartum Rh isoimmunization accounts for between 1% and 2% of all cases.
After a spontaneous abortion, there is a 1–2% chance of isoimmunization, whereas there is a 4–5% chance after an induced abortion. It is unknown what the risk is associated with an early abortion caused by medication, although it is likely to be rather low because of the limited volume of embryonic red cells.
It is possible for there to be an increase in the volume of fetomaternal hemorrhage in the event of a cesarean delivery, multifetal gestation, placenta previa or abruption, manual removal of the placenta, and several prenatal procedures such as chorionic villus sampling, amniocentesis, and external cephalic version.
In susceptible pregnancies, the incidence of isoimmunization has been reduced to less than one percent thanks to the use of Rho(D) immunoglobulin as a preventative measure.


Precautionary measures 
ABO and Rh blood type on all pregnant women and before giving blood transfusions
Screening for antibodies beginning in the first trimester of pregnancy
The only type of sensitization that Rh immunoglobulin can prevent is that to the D antigen.
 Cell-free fetal (Cff) DNA testing with selective delivery of Rh immunoglobulin when the fetus tests Rh-positive has been demonstrated to be as successful at preventing new Rh sensitization when compared to the routine administration of Rh-immunoglobulin to all Rhnegative women. This conclusion was reached after comparing the two methods using the same fetus as the subject of the testing. Taking this course of action prevents the utilization of Rh immunoglobulin when it is not required.
● In the United States at this time, the usage of routine Rh immune globulin administration is currently more cost-effective than the utilization of Cff DNA testing. Rho(D) immunoglobulin, also known as RhIG, RhoGAM, HyperRHO, and Rhophylac, is administered as a kind of prophylaxis to Rh-negative women who have not been sensitized to the disease.
- The possibility of a miscarriage or an actual miscarriage (controversial in the first 12 weeks of pregnancy).
– The termination of pregnancies for therapeutic purposes (there is no evidence for or against the use of prophylaxis in medication-induced abortions before 6 to 7 weeks).
– Ectopic pregnancy – Evacuation of molar pregnancy – Intrauterine death of the fetus – Antepartum hemorrhage – Trauma to the abdomen – Amniocentesis or cordocentesis – Chorionic villus sampling – External cephalic version – Within 72 hours of the delivery of a Rh-positive infant – Given routinely at 28 weeks' gestational age.
Prophylaxis avoids sensitization, which may have an influence on a subsequent pregnancy, but it has very little impact on the pregnancy that is currently taking place.
● Dosage for prophylaxis: 50 micrograms (up to 120 micrograms) dose for events occurring up to 12 weeks into a pregnancy; 300 micrograms dose for events occurring after 12 weeks into a pregnancy; In the event of a significant fetal–maternal hemorrhage (more than 30 mL of whole blood), it is possible that higher doses will be necessary.

Conditions That Often Occur Together 
Neonatal jaundice is a common condition, but hemolytic disease of the fetus and newborn (HDFN) is a condition that occurs less frequently.
fetal hydrops (very uncommon) kernicterus (extremely uncommon)
Please see the article on "Erythroblastosis Fetalis.

Diagnosed with neonatal jaundice, kernicterus signs and symptoms (choreoathetoid movements, gaze abnormalities, dental enamel dysplasia), and fetal hydrops or fetal death in utero if the condition is severe (for more information, see the article titled "Erythroblastosis Fetalis").

Other blood group (non-Rh) isoimmunization Nonimmune fetal hydrops Hereditary spherocytosis RBC enzyme abnormalities ABO incompatibility Other blood group (non-Rh) isoimmunization Nonimmune fetal hydrops Nonimmune fetal hydrops Nonimmune fetal hydrops

Results From the Laboratory 

Initial Examinations (in the lab and with imaging)
a successful indirect Coombs test (antibody screen) performed during pregnancy with a positive result
 The blood type of the father; if this is unknown or heterozygous, amniocentesis utilizing PCR to determine the fetal antigen type is very sensitive (98.7%) and specific (100%); this is the method that is currently common in the United States.
 The cell-free fetal DNA (Cff DNA) test is one that is routinely done in many nations in Europe. This test is also accessible in the United States, although it is not a generally covered benefit at this time. It has an accuracy of 97.1%, a sensitivity of 97.2%, and a specificity of 96.8% when it comes to detecting the Rh genotype in fetal blood.
 Rosette test (qualitative detection of fetomaternal bleeding); if positive, perform Kleihauer-Betke test (fetal hemoglobin acid elution, Hb F slide elution) or flow cytometry (more sensitive but not generally available) to quantify an acute fetal–maternal bleed. Rosette test (quantitative detection of fetomaternal bleeding).
 Determine the severity of the anemia in the fetus.
 Testing for blood type and the direct Coombs reaction in newborns
Additional Assessments, as well as Other Important Factors
Prior administration of Rho(D) could result in a weakly positive anti-D (indirect Coombs test) in the mother and a positive direct Coombs test in the newborn. This could be due to a false positive.

Treatment of the fetus may include, but is not limited to, the following, depending on the severity of the fetal involvement:
– Intrauterine transfusion – Early delivery (usually no later than 37 to 38 weeks gestation) Treatment of the newborn may involve the following: – Intrauterine transfusion – Early delivery (generally no later than 37 to 38 weeks gestation)
- Blood transfusions for exchange
– Blood exchange after birth – Phototherapy – There is insufficient information about the effectiveness of IVIG in lowering the requirement for blood exchange.

Pregnancies in women who are Rh-sensitive are often managed at tertiary care facilities by maternal–fetal medicine specialists. This is due to the highly specialized and potentially dangerous treatment procedures that are required to manage these pregnancies.


Initial observation of the infant either as an inpatient or in a nursery specializing in special care in the event that treatment interventions are required.

Continued Patient Observation and Monitoring
During the antepartum interval, outpatient ambulatory management is appropriate to use in the vast majority of patients.
 Antibody titer should be evaluated monthly in isoimmunized women until 24 weeks, and then every two weeks thereafter throughout the woman's first affected pregnancy; a titer of less than 1:16 signals the need for additional testing.
An Rhpositive fetus in the patient's current pregnancy should be regarded at risk regardless of the patient's antibody titers if the patient has previously given birth to an infant who was impacted by the condition.
– Testing of the fetal heart rate using ultrasound to evaluate the health of the fetus. – Using ultrasound to estimate the amount of blood flowing to the brain using a Doppler technique (this should only be done by medical professionals who have received proper training). If the peak MCA systolic velocity is greater than 1.5 multiples of the median for the gestational age, then additional testing (cordocentesis) is required in order to diagnose fetal anemia (4) [A].
– Umbilical blood sampling (cordocentesis) for fetal blood type, hematocrit, reticulocyte count, and presence of erythroblasts – Amniocentesis for amniotic fluid bilirubin levels – Amniocentesis for fetal lung maturity if early delivery is a therapy option. – Umbilical blood sampling (cordocentesis) for fetal blood type, 

The prognosis is that babies born to mothers whose pregnancies were seriously impacted have a survival chance of more than 80 percent if they receive the right monitoring and treatment.
In spite of the severity of the disease, most patients who survive it have a favorable neurologic result.
fetuses who are diagnosed with hydrops have a higher chance of death as well as a greater potential for neurologic impairment. the disease is likely to be more severe in subsequent pregnancies that are impacted.

Complications include miscarriage due to blood sampling from the umbilical cord, miscarriage due to intrauterine transfusion, and fetal discomfort requiring immediate delivery.

---